Does one size fit all? Risks and benefits of neoadjuvant chemoradiation in patients with clinical stage IIA rectal cancer requiring abdominoperineal resection

Neoadjuvant chemoradiotherapy (nCRT) has become the standard of care for locally advanced rectal cancer, decreasing locoregional recurrence, yet with an unclear survival advantage. We aimed to assess the benefit of nCRT on oncologic and perioperative outcomes of patients with clinical stage IIA rectal adenocarcinoma treated with abdominoperineal resection (APR).

Source: American Journal of Surgery - October 21, 2019 Category: Surgery Authors: Mariane Gouv êa Monteiro de Camargo, Xhileta Xhaja, Alexandra Aiello, David Liska, Emre Gorgun, David W. Dietz, Matthew F. Kalady, Conor P. Delaney, Scott R. Steele, Michael A. Valente Source Type: research